|
Latest News (click links below to view)
Dr. Marc Siegel and Kevin Sills Join Oragenics’ Board of Directors, posted 04.30.08
Items of Interest:
• Oragenics' SMaRT Replacement Therapy™ was featured on a segment called, "Conquering Cavities" by Lynn Martinez of FOX 7. READ > >
• Oragenics' SMaRT Replacement Therapy™ was featured on a segment called, "A Cure For Cavities?" by Dr. Joette Giovinco of FOX 13 Tampa Bay. READ > >
• View MU1140™ Poster Showing Study Results (Click Here)
Preclinical study results with MU1140™ that were recently presented in a poster at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago, September 17-20, 2007.
• Dr. Jeffrey Hillman and his collaborators describe their antibiotic research in a chapter of a new text book entitled Research and Applications in Bacteriocins (M.A. Riley and O. Gillor eds.). The title of the chapter is "Lantibiotic Production by Streptococcus mutans; their Uses in Replacement Therapy for the Prevention of Dental Caries and as Antibiotics for the Treatment of Various Infectious Diseases".
• Florida Trend: The Magazine of Florida Business "Filling the Void"
Professor's discovery offers potential for a lifetime of cavity protection. While Dr. Hillman is awaiting a decision from the FDA on Replacement Therapy that can potentially provide lifetime protection from cavities with one treatment, he is working on other dental treatments. Probiora3™, if used daily, can also protect against cavities and will hopefully be available on the market next year. July 2007
• Dr. Jeffrey Hillman and his collaborators describe their antibiotic research in a chapter of a new text book entitled Research and Applications in Bacteriocins (M.A. Riley and O. Gillor eds.). The title of the chapter is "Lantibiotic Production by Streptococcus mutans; their Uses in Replacement Therapy for the Prevention of Dental Caries and as Antibiotics for the Treatment of Various Infectious Diseases".
• Oragenics' SMaRT Replacement Therapy™ was featured on a health segment by John Fowler of KTVU in San Francisco, Channel 2 entitled "Breakthrough New Cavity Treatment".
READ > >
• Dr. Jeffrey Hillman and his collaborators describe their antibiotic research in a chapter of a new text book entitled Research and Applications in Bacteriocins (M.A. Riley and O. Gillor eds.). The title of the chapter is "Lantibiotic Production by Streptococcus mutans; their Uses in Replacement Therapy for the Prevention of Dental Caries and as Antibiotics for the Treatment of Various Infectious Diseases".
|
Recent News
Oragenics, Inc. Announces the Early Exercise of Warrants, posted 03.06.08 | Description: Early Exercise of Warrants issued to investors in the August 2007 investment round in Oragenics have been exercised early at a price of $0.44. This early exercise resulted in aggregate proceeds to the Company of $1.49 million.
>> CLICK HERE TO READ the full document<<
Oragenics to Receive European Patent for its IVIAT™ Biomarker Technology, posted 12.18.07 | Description: The European Patent Office of its intention to grant a European patent for "Identification of Microbial Polynucleotides Expressed During Infection of a Host" or the In Vivo Induced Antigen Technology, IVIAT™.
>> CLICK HERE TO READ the full document<<
Oragenics, Inc. Selects Qualia Clinical Services to Conduct SMaRT™ Phase 1 Trial, posted 12.07.07 | Description: Initiation of this Phase 1b safety study is an important milestone for us and for advancing clinical knowledge regarding the replacement therapy concept as a means for treating or preventing bacterial infections...
>> CLICK HERE TO READ the full document<<
Oragenics Receives FDA Go-Ahead for SMaRT Replacement Therapy™ Trial, posted 11.01.07 | Description: Oragenics receives FDA Investigational New Drug Application (IND) approval to proceed with SMaRT Replacement Therapy™ second Phase 1 clinical trial.
>> CLICK HERE TO READ the full document<<
Drug-Resistant Staph Kills More Americans than AIDS, posted 10.19.07 | Description: JAMA reports nearly 19,000 Americans die each year from drug-resistant staph (MRSA or Superbug) "MU1140™ represents a major new class of antibiotics...
>> CLICK HERE TO READ the full document<<
President's Letter to Shareholders, posted 10.04.07 | Description: Robert T. Zahradnik, Ph.D., President & CEO, discusses Oragenics' progress and plans for the remaining year.
>> CLICK HERE TO READ the full document<<
Oragenics' Lead Antibiotic Effectively Kills Vancomycin-Resistant Bacteria, posted 09.05.07 | Description: MU1140™ demonstrated effective at killing pathogenic bacteria that are resistant to a variety of antibiotics...
>> CLICK HERE TO READ the full document<<
Oragenics Receives Clinical Hold Letter from FDA, posted 08.15.07 | Description: Oragenics's SMaRT Replacement Therapy™ cannot initiate human study until it responds to FDA hold issues
>> CLICK HERE TO READ the full document<<
Oragenics Completes $1.17 Million Financing , posted 08.13.07 | Description: Oragenics completed an equity based financing with a group of accredited investors that includes existing shareholders.
>> CLICK HERE TO READ the full document<<
AMEX Accepts Oragenics’ Plan to Regain Compliance with Continued Listing Standards, posted 07.09.07 | Description: American Stock Exchange has accepted Oragenics' plan to regain compliance with continued listing AMEX standards.
>> CLICK HERE TO READ the full document<<
Dr. Ron Evens Joins Oragenics' Board of Directors, posted 06.19.07 | Description: Dr. Evans' tremendous depth of pharmaceutical industry experience will contribute significantly to Oragenics' growth.
>> CLICK HERE TO READ the full document<<
President's Letter to Shareholders, posted 05.18.07 | Description: President's Letter to Shareholders from Robert T. Zahradnik, Ph.D., Oragenics President & CEO
>> CLICK HERE TO READ the full document<<
Oragenics, Inc. Receives Noncompliance Warning Letter From American Stock Exchange, posted 05.07.07 | Description: Oragenics received warning from the American Stock Exchange (AMEX) advising the Company is not in compliance...
>> CLICK HERE TO READ the full document<<
Oragenics, Inc. Director George Hawes Resigns, posted 05.04.07 | Description: George Hawes is leaving his position as a member of the Board, effective immediately. Mr. Hawes has served...
>> CLICK HERE TO READ the full document<<
All Others (HERE)
|